A single dose cut a blood-clotting test time by more than half in two people.

Hemab Therapeutics (COAG) reported initial clinical data for sutacimig in Factor VII deficiency, showing a single dose reduced blood-clotting test time by over half in two participants. Preclinical data for HMB-003 showed reduced severe menstrual bleeding in a monkey model. Sutacimig is in Phase 2b, while HMB-003 is in Phase 1, with initial data expected in mid-2027.

Original reporting
Published Nov 4, 2026, 2:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$COAG
Bullish
high confidence
Mentioned
$COAG
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$COAGBullishMed
01

Why it matters

The disclosed data provide the first human evidence of sutacimig's mechanism, potentially differentiating it from existing therapies and attracting partnership or licensing interest.

02

Market read

First‑time positive Phase 2b data for a novel therapy in a rare bleeding disorder, likely to move COAG stock ahead of the ASH conference.

03

What to watch

Regulatory timelines and reimbursement pathways for rare‑disease treatments could delay commercial impact.

Relevance 8/10Novelty 8/10Timing: ahead of ASH meeting in December 2026

Background

Hemab Therapeutics (Nasdaq:COAG) is a clinical‑stage biotech focused on blood‑coagulation disorders. The company holds Fast Track, Orphan, and PRIME designations for sutacimig.

Company-level read

Ticker impact

$COAGBullishHigh confidence
Context

Hemab Therapeutics disclosed first Phase 2b clinical data for sutacimig in Factor VII deficiency, showing sustained Factor VII accumulation and halved prothrombin time in two patients.

Expected impact

likely upward pressure as market prices in the encouraging efficacy signal

Evidence & confidence

First‑time disclosure of meaningful pharmacodynamic results for a novel bispecific antibody in a rare bleeding disorder, with FDA Fast Track and orphan designations already granted.

Market effects

May boost interest in biotech firms developing rare‑disease therapies and antifibrinolytic agents.

Limited to US biotech sector; no broader regional effect.

Highlights growing pipeline activity in coagulation disorders, potentially influencing global biotech funding trends.

Counterpoint

Early data from only two patients; efficacy and safety remain unproven at scale, risk of later setbacks.

Key entities

  • Hemab Therapeutics

    Clinical‑stage biotech developing sutacimig and HMB-003.

  • American Society of Hematology (ASH)

    Venue where the data will be presented.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A